Neogenomics Logo
Menu

Delivering a complete gynecologic cancer solution for you and your patients ​

Trust the experts with over 20 years of experience. 

hero anchor

Over 118,000 women are newly diagnosed with gynecologic cancer annually in the U.S.¹

The NeoGenomics gynecologic cancer solution supports the care continuum with tests that detect genomic alterations relevant to diagnosis, therapy selection, prognosis, and clinical trial options. With deep genomic expertise and a commitment to precision, NeoGenomics empowers clinicians to deliver more informed, targeted care for patients facing gynecologic cancers.

NEO PanTracer LBx

Liquid biopsy NGS comprehensive genomic profile targeting 514 genes for SNVs, InDels, CNVs, and fusions with MSI-High and bTMB for advanced stage pan-solid tumors.

Turnaround Time: 7 Days

Learn more about this test

NeoTYPE® Ovarian Tumor Profile

The NeoTYPE Ovarian Tumor Profile characterizes primary or metastatic ovarian tumors of any histological subtype for the most significant genetic changes relevant to therapy decisions, prognosis, and clinical research.

Turnaround Time: 14 Days

Learn more about this test

Comprehensive HRD Testing for Informed Ovarian Cancer Treatment

Approximately one in two patients with advanced ovarian cancer is HRD-positive,2 making HRD testing a critical step in guiding personalized treatment. Despite global guidelines recommending BRCA and HRD testing, many eligible patients remain untested—limiting access to biomarker-driven therapies.3

PanTracer Tissue + HRD offers comprehensive genomic profiling (CGP) with integrated HRD assessment. Our advanced HRD assessment covers BRCA1/2 mutation status and tumor genomic instability score (GIS), including LOH, TAI, and LST, to guide personalized treatment decisions.

With real-time molecular insights, PanTracer Tissue + HRD supports more informed, precise, and effective treatment strategies across the ovarian cancer care continuum.

 

Guideline-driven biomarker detection for ovarian cancer4-7

Ovarian
Cervical
Endometrial
Ovarian
Ovarian cancer biomarkers
Cervical
Cervical cancer biomarkers
Endometrial
Endometrial cancer biomarkers

Additional tests for gynecologic cancer

HER2 (Other)

The HER2 (Other) IHC test is used to provide HER2 status to aid in determining anti-HER2 targeted therapies for various tumor types.

Turnaround Time: 1-2 Days

Learn more about this test

HPV DNA Tissue Testing

HPV DNA Tissue Testing is performed on FFPE tissue. It uses PCR and fragment analysis for qualitative detection and genotyping of human papillomavirus (HPV) low risk types 6/11 and high risk types 16, 18, 31, 33, 45, and 58.

Turnaround Time: 7 Days

Learn more about this test

BRCA1/2 Mutation Analysis for Tumors

BRCA1 (breast and ovarian cancer susceptibility protein 1) is a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor.

Turnaround Time: 14 Days

Learn more about this test

FOLR1 IHC

The FOLR1 is an FDA-approved IHC assay intended for use in the assessment of Folate Receptor alpha (FRα) protein in ovarian cancer tissue.

Turnaround Time: 1-2 Days

Learn more about this test

PD-L1 22C3 FDA (KEYTRUDA®) for Cervical

The PD-L1 IHC 22C3 pharmDx test is indicated as an aid in identifying patients with recurrent or metastatic cervical squamous cell cancer for treatment with KEYTRUDA® (pembrolizumab).

Turnaround Time: 1-2 Days

Learn more about this test

FOLR1 stats

FOLR1

Folate receptor alpha (FRα), also known as FOLR1, is an actionable biomarker expressed in approximately 90% of ovarian cancers7 and minimally in normal tissues—making it an ideal target for FOLR1-directed therapies. The FDA-approved FOLR1 IHC assay is designed to assess FRα expression in ovarian cancer tissue and guide treatment selection.

References

  1. American Cancer Society. Cancer Facts & Figures 2025.  Atlanta: American Cancer Society; 2025. 

  2. Nogueira Rodrigues A, Souto AKdBA, de Andrade DAP, et al. Homologous recombination deficiency test validation in patients with high-gradeadvanced ovarian cancer. Front Mol Biosci. 2025;12:1524594. doi:10.3389/fmolb.2025.1524594 

  3. Bender S. Physician Gaps in Genetic Testing Knowledge May Impact Ovarian Cancer Care. Am J Manag Care. Published March 26, 2024. Available at:https://www.ajmc.com/view/physician-gaps-in-genetic-testing-knowledge-may-impact-ovarian-cancer-care. Accessed March 28, 2025. 

  4. Moore DC, Guinigundo AS. The role of biomarkers in guiding clinical decision-making in oncology. J Adv Pract Oncol. 2023;14(3):241-248.doi:10.6004/jadpro.2023.14.3.17 

  5. Hollasch M. New ADCs join NCCN guidelines for gynecologic cancers representing step forward. OncLive. Published December 10, 2024. Accessed May 7, 2025.

  6. Helwick C. NCCN Clinical Practice Guidelines in Oncology: 2023 Updates. The ASCO Post. Published May 25, 2023. Accessed May 7, 2025.

  7. Roche Diagnostics. Roche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identifyovarian cancer patients eligible for ELAHERE. Published November 18, 2024. Accessed April 11, 2025.https://diagnostics.roche.com/global/en/news-listing/2024/roche-receives-ce-mark-for-ventana-folr1--folr1-2-1--rxdx-assay-.html